MAGE-C2/CT10 Protein Expression in Prostate Cancer
Author Information
Author(s): Lotta von Boehmer, Lukas Keller, Ashkan Mortezavi, Maurizio Provenzano, Giovanni Sais, Thomas Hermanns, Tullio Sulser, Achim A. Jungbluth, Lloyd J. Old, Glen Kristiansen, Maries van den Broek, Holger Moch, Alexander Knuth, Peter J. Wild
Primary Institution: University Hospital Zurich, Zurich, Switzerland
Hypothesis
The study aims to analyze the extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer.
Conclusion
MAGE-C2/CT10 expression is a predictor of biochemical recurrence after radical prostatectomy and is more frequent in advanced prostate cancer.
Supporting Evidence
- MAGE-C2/CT10 expression was found in 3.3% of primary prostate carcinomas.
- Expression was significantly higher in metastatic (16.3%) and castration-resistant prostate cancer (17%).
- MAGE-C2/CT10 expression was identified as an independent predictor of biochemical recurrence.
Takeaway
This study found that a protein called MAGE-C2/CT10 is found more often in advanced prostate cancer and can help predict if the cancer will come back after surgery.
Methodology
The study used immunohistochemical analysis on tissue microarrays from prostate cancer patients to evaluate MAGE-C2/CT10 expression.
Participant Demographics
The study included 348 prostate carcinomas from radical prostatectomies, 29 castration-refractory prostate cancer samples, and 45 benign hyperplasia samples.
Statistical Information
P-Value
p=0.015
Confidence Interval
95% CI 17-86 months for MAGE-C2/CT10 positive tumors
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website